471Authorisation condition for opioid dependency treatment

471 Authorisation condition for opioid dependency treatment licences—Act, s 44 (1) (b) and (2) (b) (1) A licence-holder’s authorisation under an opioid dependency treatment licence is subject to the following conditions: (a) the licence-holder must ensure that a person to whom buprenorphine or methadone is administered under the licence signs a written acknowledgment in accordance with subsection (2) that the medicine has been administered to the person;

(b) a purchase order issued by the licence-holder to obtain buprenorphine or methadone under the licence is a complying purchase order. Note 1 Written includes in electronic form (see Act, dict). Note 2 For licence conditions, see the Act, s 89. (2) For subsection (1) (a), the acknowledgment must include the (a) the approved name or brand name of the medicine administered; (b) the form, strength and quantity of the medicine administered; (c) the date the medicine is administered. Division 9.5.5 Pharmacy medicines rural communities licences Note For other provisions about pharmacy medicines rural communities licences, see pt 14.6.